New Urine Test for Womb Cancer Offers Hope for Easier Diagnosis
A new urine test for womb cancer, alongside tests using vaginal fluid, could eventually make diagnosing the disease simpler and less invasive for thousands of patients.
Researchers are investigating whether biological signs of endometrial cancer — the most common form of womb cancer — can be detected in urine and cervico-vaginal fluid.
The idea is relatively simple: tumours can release cells, DNA, proteins and other biological material. Some of these cancer-related signals can make their way into urine or vaginal fluid, where researchers may be able to identify them without taking tissue directly from the womb.
Recent scientific reviews have found encouraging results from several types of urinary biomarkers, including DNA methylation markers, mutations and cytology. Researchers have also identified promising protein signatures in cervicovaginal fluid.
The potential benefit is significant.
Instead of immediately putting many patients through invasive investigations, doctors could eventually use a simple sample to identify who is at higher or lower risk and determine who most urgently needs further testing.
However, researchers stress that these approaches are still being developed and validated. They are not currently a replacement for established diagnostic investigations such as ultrasound, hysteroscopy and biopsy.
Why Womb Cancer Diagnosis Needs to Improve
Womb cancer, also known as uterine cancer, usually develops in the lining of the uterus.
This lining is called the endometrium, which is why the most common form of womb cancer is known as endometrial cancer.
One of the biggest advantages doctors have when diagnosing the disease is that it frequently produces symptoms relatively early.
The most important warning sign is unusual vaginal bleeding.
This can include bleeding after menopause, bleeding between periods, unusually heavy periods or pink or watery blood-stained vaginal discharge.
But abnormal bleeding does not automatically mean someone has cancer.
Many benign conditions can produce similar symptoms.
The challenge for doctors is therefore identifying the relatively small proportion of symptomatic patients who have cancer without subjecting everyone to unnecessary invasive investigations.
IMAGE PLACEMENT: Add a simple medical illustration of the uterus here.
Suggested alt text: Diagram showing the uterus and endometrium where most womb cancers begin.
How Womb Cancer Is Currently Diagnosed
Someone experiencing symptoms of womb cancer will normally begin by speaking to their GP.
Depending on their symptoms and circumstances, investigations may include an examination and a transvaginal ultrasound.
A transvaginal ultrasound involves inserting a small ultrasound probe into the vagina to produce images of the womb and measure the thickness of its lining.
If doctors remain concerned, further investigation may be required.
This can include a hysteroscopy, in which a narrow instrument containing a camera is passed through the cervix to examine the inside of the uterus.
Doctors may also perform an endometrial biopsy, taking a small sample of tissue from the womb lining for laboratory examination.
These investigations are critical because they allow doctors to diagnose or rule out cancer.
But they can also be uncomfortable, painful or distressing for some patients.
That is why scientists are interested in finding a reliable, less invasive first-line test.
How Could a Urine Test Detect Womb Cancer?
Urine might seem an unusual place to search for womb cancer.
The biology, however, makes the idea plausible.
Cancer can produce molecular changes that may be detectable elsewhere in the body.
Researchers studying urine have looked for several different types of biomarkers, including:
DNA mutations associated with tumour cells, changes in DNA methylation, proteins and peptides, microRNAs, metabolites and cancer cells shed from the reproductive tract.
Research published in the British Journal of Cancer in August 2026 reviewed the rapidly developing evidence in this field.
It concluded that urine is particularly attractive because samples are non-invasive, inexpensive, easy to collect and suitable for repeated testing.
Some studies of DNA methylation and mutation-based urine tests have reported sensitivity and specificity above 80% or 90% in symptomatic populations.
Those results are encouraging, although performance varies between techniques and studies.
The review concluded that urine biomarkers are not yet ready for general population screening but could eventually become useful for deciding which symptomatic patients need more invasive investigations.
Vaginal Fluid Could Provide Another Clue
Urine is not the only easily collected sample attracting attention.
Scientists are also studying cervico-vaginal fluid.
This fluid may contain biological material shed directly from the female reproductive tract.
Researchers from the University of Manchester and collaborating institutions recently reviewed protein biomarkers found in cervico-vaginal fluid.
Several combinations of proteins showed promising ability to distinguish endometrial cancer from non-cancer samples.
One five-protein panel achieved an area-under-the-curve, or AUC, measurement of around 0.95 in the evidence reviewed.
AUC is a statistical measure researchers use to evaluate how well a diagnostic test separates people with a condition from those without it.
An AUC close to 1 represents stronger discrimination.
But even promising results like these do not mean a test is ready to enter everyday healthcare.
Researchers say the biomarkers need rigorous validation in large, prospective, multicentre studies before they can be used routinely in clinical practice.
IMAGE PLACEMENT: Add an illustration showing a simple urine sample and vaginal swab here.
Suggested alt text: Urine and vaginal fluid samples being investigated for less-invasive womb cancer diagnosis.
Vaginal Swab Research Is Also Showing Promise
Another promising approach involves detecting abnormal DNA in a vaginal swab.
A multicentre study presented at the 2026 American Society of Clinical Oncology annual meeting evaluated DNA methylation markers in vaginal samples.
Researchers analysed valid samples from 670 participants in the study.
A four-marker DNA panel showed an AUC of 0.97 for endometrial cancer.
At a specificity threshold of 85%, the model achieved approximately 96% sensitivity for endometrial cancer across all stages in the study population.
Sensitivity describes how effectively a test identifies people who actually have the disease.
The researchers concluded that the findings support the potential development of a non-invasive vaginal swab test that could help rule out endometrial cancer.
But they also stressed that researchers need to conduct further studies to finalise the marker panel and algorithm before validating the test.
That distinction matters.
These results are promising research findings — not proof that a new diagnostic test can immediately replace a biopsy.
Could Patients Eventually Collect Samples at Home?
One of the most attractive possibilities is that some samples could eventually be collected at home.
Urine is particularly suited to this approach.
Instead of attending hospital immediately for an invasive procedure, a patient could potentially provide a urine sample that is sent to a laboratory for analysis.
A similar approach might eventually become possible with some vaginal sampling methods.
That could make testing more accessible and potentially reduce barriers for people who are reluctant to undergo invasive gynaecological examinations.
Home sampling could be particularly valuable for people who require repeated monitoring because they have a higher inherited risk of womb cancer.
However, exactly how such services would operate would depend on the final tests, their accuracy and approval by healthcare regulators.
UK Researchers Are Already Testing New Approaches
The UK is playing an important role in this research.
A five-year research programme recruiting participants from 2026 is evaluating new approaches to identifying endometrial cancer.
One tool, known as PREDICT-EC, combines information such as patient characteristics, symptoms and scan results with a simple urine test for blood to produce a risk score.
Participants are providing urine, blood and vaginal samples so researchers can investigate how accurately different tools identify womb cancer and precancerous disease.
The objective is not simply to invent another laboratory test.
Researchers want to build a better pathway that determines who really needs invasive investigation.
Could It Reduce Unnecessary Biopsies and Hysteroscopies?
This is potentially where the biggest benefit lies.
Imagine 100 patients arrive at a clinic with symptoms that could indicate womb cancer.
Doctors cannot simply assume that most do not have cancer.
They need a reliable method of identifying the people who require urgent investigation.
If a highly accurate urine or vaginal-fluid test could identify very-low-risk patients, some could potentially avoid unnecessary hysteroscopies or biopsies.
Higher-risk patients could meanwhile be prioritised for further investigation.
That could make the diagnostic system both more comfortable for patients and more efficient for healthcare services.
But the accuracy would need to be extremely reliable.
A test designed to rule out cancer must minimise the risk of falsely reassuring someone who actually has the disease.
Could the Test Detect Womb Cancer Earlier?
Earlier diagnosis is another potential advantage.
Womb cancer often causes abnormal bleeding before the disease becomes advanced.
That creates an opportunity for early detection.
If a simple urine or vaginal test makes it easier for patients to be investigated promptly, cancers might be identified earlier.
Researchers are particularly interested in developing tests that are simple enough to repeat.
This could eventually prove useful for people with conditions such as Lynch syndrome, an inherited condition that increases the risk of several cancers, including womb and bowel cancer.
Scientists have discussed the possibility that non-invasive testing could eventually help monitor higher-risk groups.
Again, this remains an area of research rather than established routine screening.
Symptoms of Womb Cancer Should Never Be Ignored
The excitement surrounding new tests should not distract from something that already saves lives: recognising symptoms and seeking medical advice.
According to NHS guidance, unusual vaginal bleeding is usually the first sign of womb cancer.
Warning signs can include:
- bleeding after menopause;
- bleeding between periods;
- periods that become unusually heavy;
- pink, bloody or watery vaginal discharge.
Pelvic discomfort and pain during sex can occur less commonly.
These symptoms have many possible causes and most people experiencing abnormal bleeding will not necessarily have cancer.
But they should still be investigated.
Anyone experiencing unexplained vaginal bleeding should contact their GP rather than waiting for new diagnostic technology to become available.
IMAGE PLACEMENT: Add an easy-to-read womb cancer symptoms graphic here.
Suggested alt text: Common womb cancer symptoms include unusual vaginal bleeding and discharge.
The Test Is Not Yet a Replacement for Biopsy
This is the most important limitation to understand.
Headlines describing a revolutionary urine test can make it sound as though patients can already provide a sample and receive a definitive womb cancer diagnosis.
That is not yet the case.
Different research groups are developing different technologies involving urine, vaginal swabs, DNA, proteins and other biomarkers.
Some have produced impressive early results.
But promising diagnostic accuracy in research does not automatically translate into reliable performance across millions of patients.
Researchers still need larger prospective studies involving people of different ages, ethnic backgrounds and risk groups, as well as people with different types and stages of womb cancer.
Scientists must also establish how these tests should fit into existing NHS diagnostic pathways.
What Happens Next?
The next stage is validation.
Researchers need to demonstrate that these tests continue to perform well when used in large and diverse patient populations.
They will need to determine how samples should be collected and stored, which biomarkers provide the strongest results and what thresholds should trigger further investigation.
Cost will matter too.
A test may be scientifically accurate but still difficult to introduce widely if specialist laboratory equipment makes it expensive or slow.
Regulators and health services will ultimately need evidence that a new test is safe, accurate and clinically useful.
If those hurdles can be overcome, urine and vaginal-fluid testing could become an important part of future womb cancer diagnosis.
Why This Research Matters
Cancer diagnosis is not only about accuracy.
The patient’s experience matters as well.
A diagnostic pathway that achieves the same or better accuracy while reducing invasive procedures could provide a major improvement.
Simple sample collection could also potentially increase accessibility.
Urine testing is already familiar to patients and healthcare professionals.
It does not require specialist equipment at the moment the sample is collected.
Vaginal swabs are also considerably simpler than taking tissue directly from the womb.
The long-term ambition is therefore compelling: to detect cancer accurately while putting patients through fewer invasive procedures.
Whether current technologies can fully achieve that goal remains under investigation.
Conclusion
A new generation of urine tests for womb cancer and vaginal-fluid tests could eventually change how researchers investigate endometrial cancer.
Scientists have discovered that urine can contain tumour-associated DNA, proteins, cells and other biological signals that may help identify the disease.
Cervico-vaginal fluid and vaginal swabs are producing similarly promising results.
Some studies have reported diagnostic performance above 90%, demonstrating why researchers are excited about the technology.
But these tests are still developing.
They are not currently a substitute for established diagnostic procedures, and larger clinical studies are necessary before they can be routinely relied upon to rule out womb cancer.
The potential, however, is considerable.
A simple urine sample or swab could one day help doctors determine which patients require invasive investigations and which can safely avoid them.
That could mean fewer unnecessary biopsies and hysteroscopies, a more comfortable experience for patients and potentially faster diagnosis for people who do have cancer.
For now, anyone experiencing unusual vaginal bleeding — particularly bleeding after menopause — should contact a healthcare professional rather than waiting for new testing methods to become available.
Frequently Asked Questions
What is the new urine test for womb cancer?
Researchers are developing several approaches that analyse urine for biological markers associated with endometrial cancer, including abnormal DNA, proteins, cells and other molecules.
Can a urine test currently diagnose womb cancer?
No, it is not a routine stand-alone NHS diagnostic test. Current urine-based approaches are still being researched and validated. Patients with suspected womb cancer may still need ultrasound, hysteroscopy and biopsy.
What is endometrial cancer?
Endometrial cancer develops in the lining of the womb, known as the endometrium. It is the most common type of womb cancer.
What is the most common symptom of womb cancer?
Unusual vaginal bleeding is the most common warning sign, particularly bleeding after menopause.
How could vaginal fluid detect womb cancer?
Cancer and precancerous cells can release proteins, DNA and other biological material that may enter vaginal fluid. Researchers are developing tests designed to identify these molecular signals.
Could the new test replace hysteroscopy?
Potentially, a validated test could help some lower-risk patients avoid unnecessary invasive procedures. However, current research does not justify replacing hysteroscopy or biopsy when those investigations are clinically required.
Is the new test available on the NHS?
Research and pilot programmes are underway, but the emerging urine and biomarker tests discussed here are not yet established as replacements for standard NHS diagnostic pathways.
